Plain-English translation of NCT06732492 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing RD13-02, a new cell therapy made from your own immune cells that have been engineered in a lab to target and attack cancer cells. The trial will enroll up to 10 patients with relapsed or refractory NK/T-cell lymphoma β a blood cancer that has either come back after treatment or is no longer responding to previous therapies. Researchers want to understand whether the medication is safe and how your body responds to it.
Patients whose NK/T-cell lymphoma comes back or stops responding to standard treatments have very few options left, and the outcomes are often poor. This trial exists to see if this new engineered cell therapy can offer hope to patients who have run out of other choices.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You would receive an intravenous infusion of the engineered cells (RD13-02 cells) through an IV line. The trial is conducted at a single center and involves close monitoring to check for safety and how your body responds to the treatment. Your participation would include regular visits for blood tests, imaging, and physical exams to track how the medication is working and to watch for any side effects.
AI-generated summary from trial data Β· Jun 24, 2026 Β· Not medical advice
China
Phase
Safety & dosing
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Nanjing Bioheng Biotech Co., Ltd.
Enrollment target
~10 participants
Started
October 2024
Primary completion
December 2026
Age range
3 Years β 70 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary β some teams are faster than others.
Central contact
Heng Mei, Ph.D&M.D
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first β no email needed to get started.